Month: September 2026

IMPORTANT NOTICE – DISCLAIMER
Not for release or distribution or publication in whole or in part, directly or indirectly, in or into Australia, Canada, Japan or the Republic of South Africa. These materials do not contain or constitute an offer for sale or the solicitation of an offer to purchase securities in the United States, Australia, Canada, Japan or the Republic of South Africa.

The securities mentioned herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States or to U.S. persons absent such registration, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. No offering of securities was made in the United States or to U.S. persons.

ATHENS, Greece, Sept. 15, 2026 (GLOBE NEWSWIRE) — “AXIA Ventures Group Ltd”, member of the Alpha Bank Group, acting as Lead Advisor and Joint Coordinator and Bookrunner and “National Bank of Greece S.A.”, acting as Co-Advisor and Joint Coordinator and Bookrunner, in connection with the Public Offering in Greece and the admission to parallel listing of all common, registered, voting shares of “Star Bulk Carriers Corp.” (the “Company”), for trading (the “Admission”) on the Main Market the Regulated Securities Market of Euronext Athens, announce the following:

On Friday, 11 September 2026, the Company completed the allocation of 4,400,000 new, common, registered, voting shares of the Company (the “New Shares”), of which 4,300,000 allocated through the Public Offering in Greece and 100,000 through the Parallel Offering to a limited group of persons, in accordance with decision no. 4/379/18.04.2006 of the Board of Directors of the Hellenic Capital Market Commission.

The final offering price of the Company’s New Shares (the “Offering Price”) was determined at €24.50 (US$28.27)¹ per New Share and is the same for all investors, Qualified and Retail, who participated in the Public Offering and the Parallel Offering.

The total proceeds of the issuance of the New Shares, before the deduction of the estimated expenses of the Public Offering, the Parallel Offering and the Admission for the Company amounts to €107.8 million (US $124.4² million), out of which the amount of €105.4 million (US$121.6² million) was raised through the Public Offering in Greece (namely €24.50 (US$28.27)¹ *4,300,000 New Shares) and the amount of €2.5 million (US$2.8² million) was raised through the Parallel Offering to a limited group of persons (namely €24.50 (US$ 28.27)¹ *100,000 New Shares).

The total valid demand expressed from investors, at the Offering Price, amounted to 26,788,512 New Shares (namely an amount of €656.3 million (US$757.3² million)), oversubscribing the 4,300,000 New Shares offered through the Public Offering, by over 6 times.

The total 4,300,000 New Shares offered through the Public Offering in Greece, were allocated based on the valid demand, expressed at the Offering Price, as follows:

• 1,743,504 New Shares (41% of the totality of the Public Offering) to Retail Investors, out of a total number of 10,618,424 New Shares for which valid demand was expressed by this specific category of investors, and
• 2,556,496 New Shares (59% of the totality of the Public Offering) to Qualifying Investors, out of a total number of 16,070,088 New Shares for which valid demand was expressed by this specific category of investors.

The two legal entities (already shareholders) controlled by members of the family of the Company’s CEO Mr. Pappas, who, in accordance with their initial intent, expressed a total demand for 248,000 New Shares, which was satisfied by 60%, meaning they were allocated 148,800 New Shares due to increased interest from institutional and retail investors and the significant oversubscription. Therefore, excluding the 148,800 New Shares corresponding to the allocation of the family of Mr. Pappas, 2,407,696 New Shares were allocated to Qualifying Investors, out of total number of 15,822,088 New Shares, for which valid demand was expressed by this specific category of investors.

According to the placing agreement, the Joint Coordinators and Bookrunners, the Lead Underwriters, and the Underwriters have not undertaken any obligation to subscribe for the shares. In addition, it is noted that the Joint Coordinators and Bookrunners, the Lead Underwriters, and the Underwriters have not submitted subscription applications in the Public Offering for their own account, with the exception of the “Optima bank S.A.”, which submitted an application for 400,000 New Shares on its own account and was allocated 52,000 New Shares.

The New Shares have not been, and will not be, registered under the U.S. federal securities laws or the securities laws of any other jurisdiction, and the New Shares may not be offered or sold in the United States or to U.S. persons unless an exemption from the registration requirements of the Securities Act is available. The New Shares were offered and sold to non-U.S. persons outside the United States in offshore transactions in reliance on Regulation S under the Securities Act.

Athens, Tuesday 15 September 2026
STAR BULK CARRIERS CORP.

Important Notice – Disclaimer

This announcement includes “forward-looking statements,” with respect to our expectations or beliefs concerning future events. Words such as, but not limited to, “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “targets,” “projects,” “likely,” “would,” “will,” “could,” “should,” “may,” “forecasts,” “potential,” “continue,” “possible” and similar expressions or phrases may identify forward-looking statements.

All forward-looking statements involve risks and uncertainties. The occurrence of the events described depend on many factors, some or all of which are not predictable or within our control. Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, market conditions, disruptions to the mechanics required to operate cross-border trading, disruptions to trading on Euronext Athens, and other technical impediments to the commencement of trading. All future written and verbal forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. We undertake no obligation, and specifically decline any obligation, except as required by law, to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

---

^{1 The Offering Price has been converted into U.S. dollars based on the Euro/U.S. dollar (EUR/USD) exchange rate as of 15.09.2026 (€1 = 1.1539 USD). (Source: “European Central Bank” at Greek market close).
2 This figure has been converted into USD based on the EUR/USD exchange rate (€1 = 1.1539 USD) as of 15.09.2026 (Source: European Central Bank at Greek market close).}

Contacts

Company:	Investor Relations / Financial Media:
Simos Spyrou, Christos Begleris	Nicolas Bornozis
Co ‐ Chief Financial Officers	President
Star Bulk Carriers Corp.	Capital Link, Inc.
c/o Star Bulk Management Inc.	230 Park Avenue, Suite 1540
40 Ag. Konstantinou Av.	New York, NY 10169
Maroussi 15124	Tel. (212) 661‐7566
Athens, Greece	E‐mail: starbulk@capitallink.com
Email: info@starbulk.com	www.capitallink.com
www.starbulk.com

FREEHOLD, NJ, Sept. 15, 2026 (GLOBE NEWSWIRE) — UMH Properties, Inc. (NYSE: UMH) (TASE: UMH), a real estate investment trust (REIT) specializing in manufactured home communities, announced that it will host its Third Quarter 2026 Financial Results Webcast and Conference Call. Senior management will discuss the results, current market conditions and future outlook on Tuesday, November 3, 2026, at 10:00 a.m. Eastern Time.

UMH’s Third Quarter 2026 results will be released on Monday, November 2, 2026, after the close of trading on the New York Stock Exchange and will be available on the Company’s website at www.umh.reit, in the Financials section.

To participate in the webcast, select the webcast icon on the homepage of the Company’s website at www.umh.reit, in the Upcoming Events section. Interested parties can also participate via conference call by calling toll free 877-513-1898 (domestically) or 412-902-4147 (internationally).

The replay of the conference call will be available at 12:00 p.m. Eastern Time on Tuesday, November 3, 2026, and can be accessed by dialing toll free 855-669-9658 (domestically) and 412-317-0088 (internationally) and entering the passcode 9497036. A transcript of the call and the webcast replay will be available at the Company’s website, www.umh.reit.

UMH Properties, Inc., which was organized in 1968, is a public equity REIT that owns and operates 145 manufactured home communities, containing approximately 27,100 developed homesites, of which 11,200 contain rental homes, and over 1,000 self-storage units. These communities are located in New Jersey, New York, Ohio, Pennsylvania, Tennessee, Indiana, Maryland, Michigan, Alabama, South Carolina, Florida and Georgia. Included in the 145 communities are two communities in Florida, containing 363 sites, and one community in Pennsylvania, containing 113 sites, that UMH has an ownership interest in and operates through its joint ventures with Nuveen Real Estate.

Contact:	Nelli Madden
	732-577-4062

# # # # #

TYLER, Texas, Sept. 15, 2026 (GLOBE NEWSWIRE) — ENvue Medical, Inc. (Nasdaq: FEED) (“ENvue” or the “Company”), a medical technology company focused on innovative solutions for enteral feeding and therapeutic ultrasound, today announced that it has received a decision from the Nasdaq Hearings Panel (the “Panel”) denying the Company’s request for continued listing on The Nasdaq Capital Market. As a result, trading of the Company’s common stock will be suspended and will begin trading on the OTC Markets under the same stock symbol, ‘FEED’, on September 16, 2026.

The Panel’s decision does not affect ENvue’s business operations, products, customers, or ongoing commercial activities. The Company continues to operate its business forward and remains focused on advancing the commercialization of the ENvue Navigation System and its broader medical technology portfolio, including PainShield® and UroShield®, while pursuing opportunities to expand adoption and commercialization of its technologies, supporting its customers and executing its commercial and operational strategy.

The Company is evaluating all available procedures and alternatives under the Nasdaq Listing Rules, including a further appeal.

“We are disappointed with the Panel’s decision and are evaluating all available paths forward,” said Doron Besser, M.D., Chief Executive Officer of ENvue Medical. “At the same time, our business continues. Our team remains focused on our customers, our products and the execution of our strategy. We will continue working to strengthen the Company and build long-term value for our shareholders.”

The Company intends to provide additional information regarding the Nasdaq process and the trading status of its common stock as appropriate.

About ENvue Medical, Inc.
ENvue Medical, Inc. (NASDAQ: FEED) is a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings. Headquartered in Tyler, Texas, with research and development in Tel-Aviv and Nesher, Israel, the Company focuses on two distinct technology platforms:

• ENvue™ Navigation Platform, developed and operated by ENvue Medical Inc., with offices in Arlington Heights, Illinois, and Tel-Aviv, Israel, is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. FDA 510(k) cleared for adult use, ENvue provides real-time bedside visualization of tube movement and supports informed decision-making during the placement procedure. Future platform expansion may include pediatric and vascular access applications.
• ENvue Medical aims to advance standards in non-invasive therapy and minimally invasive navigation, with a commitment to patient safety, clinical usability, and technology innovation across a range of healthcare environments.
• Acoustic-based therapeutic technologies, including PainShield® and UroShield®, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms.

Forward-Looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. These forward-looking statements include, but are not limited to: statements regarding continued growth in feeding tube sales, expected utilization of the ENvue™ Navigation Platform across the Company’s installed hospital base, anticipated recurring consumable demand associated with the Company’s commercial model, the potential for expanded adoption within existing hospital customers and health systems, and future expectations for the ENvue business. For example, the Company is using forward-looking statements when it discusses the expected trading of its common stock on the OTC Markets on September 16, 2026, its long-term business plans and that it continues to work to strengthen the Company and build long-term value for its shareholders. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: (i) market acceptance of the Company’s existing and new products; (ii) clinical performance and operational outcomes; (iii) delays or complications in product implementation; (iv) intense competition in the medical device industry; (v) product liability or performance issues; (vi) limitations in manufacturing or supply chain capabilities; (vii) reimbursement limitations; (viii) intellectual property protection; (ix) healthcare regulatory changes in the U.S. and abroad; and (x) the need for additional capital. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Investors and security holders are urged to read these documents free of charge at www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.

Investor Contact:
KCSA Strategic Communications
Valter Pinto, Managing Director
PH: (212) 896-1254
envue@kcsa.com 

Media Contact:
KCSA Strategic Communications
Michaela Fawcett, Senior Account Director
PH: (978) 995-4683
envue@kcsa.com